Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,005 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HBV-integrated local genomic alterations reveal multicentric independent occurrences of multifocal HCC.
Zou H, Wang Y, Lu L, Yao K, Wang C, Ma K, Zhu C, Guo Z, Feng Y, Wu Z, Song M, Zhou B, Hu X, Han B, Guo W, Qiu F, Zhang B, Qi X, Wang X, Wang M, Pan G, Sun Q, Cao J, Gong S, Zhao Z, Sun C, Lu S, Tian L. Zou H, et al. Among authors: tian l. Clin Transl Med. 2023 Jun;13(6):e1313. doi: 10.1002/ctm2.1313. Clin Transl Med. 2023. PMID: 37382888 Free PMC article. No abstract available.
Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients.
Zhang W, Hu B, Han J, Wang Z, Ma G, Ye H, Yuan J, Cao J, Zhang Z, Shi J, Chen M, Wang X, Xu Y, Cheng Y, Tian L, Wang H, Lu S. Zhang W, et al. Among authors: tian l. Front Oncol. 2021 Oct 19;11:747950. doi: 10.3389/fonc.2021.747950. eCollection 2021. Front Oncol. 2021. PMID: 34737958 Free PMC article.
Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
Zhang W, Tong S, Hu B, Wan T, Tang H, Zhao F, Jiao T, Li J, Zhang Z, Cai J, Ye H, Wang Z, Chen S, Wang Y, Li X, Wang F, Cao J, Tian L, Zhao X, Chen M, Wang H, Cai S, Hu M, Bai Y, Lu S. Zhang W, et al. Among authors: tian l. J Immunother Cancer. 2023 Sep;11(9):e007366. doi: 10.1136/jitc-2023-007366. J Immunother Cancer. 2023. PMID: 37730273 Free PMC article. Clinical Trial.
8,005 results